ASMB - ASSEMBLY BIOSCIENCES, INC.
IEX Last Trade
14.88
-0.180 -1.210%
Share volume: 100
Last Updated: Fri 27 Dec 2024 07:23:55 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$15.06
-0.18
-1.20%
Fundamental analysis
21%
Profitability
0%
Dept financing
6%
Liquidity
50%
Performance
38%
Performance
5 Days
3.08%
1 Month
-8.62%
3 Months
-2.60%
6 Months
5.34%
1 Year
57.45%
2 Year
5.05%
Key data
Stock price
$14.88
DAY RANGE
$15.06 - $15.06
52 WEEK RANGE
$0.84 - $19.93
52 WEEK CHANGE
$56.28
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: John G. McHutchison
Region: US
Website: assemblybio.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: assemblybio.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Assembly Biosciences, Inc. discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.
Recent news